197 related articles for article (PubMed ID: 29602798)
1. Hepatic Abundance and Activity of Androgen- and Drug-Metabolizing Enzyme UGT2B17 Are Associated with Genotype, Age, and Sex.
Bhatt DK; Basit A; Zhang H; Gaedigk A; Lee SB; Claw KG; Mehrotra A; Chaudhry AS; Pearce RE; Gaedigk R; Broeckel U; Thornton TA; Nickerson DA; Schuetz EG; Amory JK; Leeder JS; Prasad B
Drug Metab Dispos; 2018 Jun; 46(6):888-896. PubMed ID: 29602798
[TBL] [Abstract][Full Text] [Related]
2. Quantitative characterization of UDP-glucuronosyltransferase 2B17 in human liver and intestine and its role in testosterone first-pass metabolism.
Zhang H; Basit A; Busch D; Yabut K; Bhatt DK; Drozdzik M; Ostrowski M; Li A; Collins C; Oswald S; Prasad B
Biochem Pharmacol; 2018 Oct; 156():32-42. PubMed ID: 30086285
[TBL] [Abstract][Full Text] [Related]
3. Normalized Testosterone Glucuronide as a Potential Urinary Biomarker for Highly Variable UGT2B17 in Children 7-18 Years.
Zhang H; Basit A; Wolford C; Chen KF; Gaedigk A; Lin YS; Leeder JS; Prasad B
Clin Pharmacol Ther; 2020 May; 107(5):1149-1158. PubMed ID: 31900930
[TBL] [Abstract][Full Text] [Related]
4. Genetic and phenotypic variation in UGT2B17, a testosterone-metabolizing enzyme, is associated with BMI in males.
Zhu AZ; Cox LS; Ahluwalia JS; Renner CC; Hatsukami DK; Benowitz NL; Tyndale RF
Pharmacogenet Genomics; 2015 May; 25(5):263-9. PubMed ID: 25794161
[TBL] [Abstract][Full Text] [Related]
5. The uridine diphosphate glucuronosyltransferase 2B15 D85Y and 2B17 deletion polymorphisms predict the glucuronidation pattern of androgens and fat mass in men.
Swanson C; Mellström D; Lorentzon M; Vandenput L; Jakobsson J; Rane A; Karlsson M; Ljunggren O; Smith U; Eriksson AL; Bélanger A; Labrie F; Ohlsson C
J Clin Endocrinol Metab; 2007 Dec; 92(12):4878-82. PubMed ID: 17698910
[TBL] [Abstract][Full Text] [Related]
6. Genotype-phenotype correlation between the polymorphic UGT2B17 gene deletion and NNAL glucuronidation activities in human liver microsomes.
Lazarus P; Zheng Y; Runkle EA; Muscat JE; Wiener D
Pharmacogenet Genomics; 2005 Nov; 15(11):769-78. PubMed ID: 16220109
[TBL] [Abstract][Full Text] [Related]
7. Genetic aspects of epitestosterone formation and androgen disposition: influence of polymorphisms in CYP17 and UGT2B enzymes.
Schulze JJ; Lorentzon M; Ohlsson C; Lundmark J; Roh HK; Rane A; Ekström L
Pharmacogenet Genomics; 2008 Jun; 18(6):477-85. PubMed ID: 18496127
[TBL] [Abstract][Full Text] [Related]
8. Genetic variations in UGT2B28, UGT2B17, UGT2B15 genes and the risk of prostate cancer: A case-control study.
Habibi M; Mirfakhraie R; Khani M; Rakhshan A; Azargashb E; Pouresmaeili F
Gene; 2017 Nov; 634():47-52. PubMed ID: 28882566
[TBL] [Abstract][Full Text] [Related]
9. Testosterone challenge and androgen receptor activity in relation to UGT2B17 genotypes.
Ekström L; Cevenini L; Michelini E; Schulze J; Thörngren JO; Belanger A; Guillemette C; Garle M; Roda A; Rane A
Eur J Clin Invest; 2013 Mar; 43(3):248-55. PubMed ID: 23294483
[TBL] [Abstract][Full Text] [Related]
10. Clopidogrel Carboxylic Acid Glucuronidation is Mediated Mainly by UGT2B7, UGT2B4, and UGT2B17: Implications for Pharmacogenetics and Drug-Drug Interactions
Kahma H; Filppula AM; Neuvonen M; Tarkiainen EK; Tornio A; Holmberg MT; Itkonen MK; Finel M; Neuvonen PJ; Niemi M; Backman JT
Drug Metab Dispos; 2018 Feb; 46(2):141-150. PubMed ID: 29138287
[TBL] [Abstract][Full Text] [Related]
11. Non-steroidal anti-inflammatory drugs interact with testosterone glucuronidation.
Sten T; Finel M; Ask B; Rane A; Ekström L
Steroids; 2009 Nov; 74(12):971-7. PubMed ID: 19643121
[TBL] [Abstract][Full Text] [Related]
12. Androgen glucuronidation: an unexpected target for androgen deprivation therapy, with prognosis and diagnostic implications.
Grosse L; Pâquet S; Caron P; Fazli L; Rennie PS; Bélanger A; Barbier O
Cancer Res; 2013 Dec; 73(23):6963-71. PubMed ID: 24121496
[TBL] [Abstract][Full Text] [Related]
13. Factors Affecting Interindividual Variability of Hepatic UGT2B17 Protein Expression Examined Using a Novel Specific Monoclonal Antibody.
Émond JP; Labriet A; Desjardins S; Rouleau M; Villeneuve L; Hovington H; Brisson H; Lacombe L; Simonyan D; Caron P; Périgny M; Têtu B; Fallon JK; Klein K; Smith PC; Zanger UM; Guillemette C; Lévesque E
Drug Metab Dispos; 2019 May; 47(5):444-452. PubMed ID: 30819787
[TBL] [Abstract][Full Text] [Related]
14. Effect of UGT2B17 deletion polymorphism on prognosis in pediatric cancer.
Ishimaru S; Yuza Y; Kaneko T; Urashima M
Pediatr Int; 2017 Apr; 59(4):427-431. PubMed ID: 27805301
[TBL] [Abstract][Full Text] [Related]
15. Multiple roles for UDP-glucuronosyltransferase (UGT)2B15 and UGT2B17 enzymes in androgen metabolism and prostate cancer evolution.
Gauthier-Landry L; Bélanger A; Barbier O
J Steroid Biochem Mol Biol; 2015 Jan; 145():187-92. PubMed ID: 24861263
[TBL] [Abstract][Full Text] [Related]
16. Bioavailability of testosterone enanthate dependent on genetic variation in the phosphodiesterase 7B but not on the uridine 5'-diphospho-glucuronosyltransferase (UGT2B17) gene.
Ekström L; Schulze JJ; Guillemette C; Belanger A; Rane A
Pharmacogenet Genomics; 2011 Jun; 21(6):325-32. PubMed ID: 21383644
[TBL] [Abstract][Full Text] [Related]
17. Genetic factors affecting gene transcription and catalytic activity of UDP-glucuronosyltransferases in human liver.
Liu W; Ramírez J; Gamazon ER; Mirkov S; Chen P; Wu K; Sun C; Cox NJ; Cook E; Das S; Ratain MJ
Hum Mol Genet; 2014 Oct; 23(20):5558-69. PubMed ID: 24879639
[TBL] [Abstract][Full Text] [Related]
18. Characterization and regulation of UDP-glucuronosyltransferases in steroid target tissues.
Bélanger A; Hum DW; Beaulieu M; Lévesque E; Guillemette C; Tchernof A; Bélanger G; Turgeon D; Dubois S
J Steroid Biochem Mol Biol; 1998 Apr; 65(1-6):301-10. PubMed ID: 9699884
[TBL] [Abstract][Full Text] [Related]
19. Loss of dihydrotestosterone-inactivation activity promotes prostate cancer castration resistance detectable by functional imaging.
Zhu Z; Chung YM; Sergeeva O; Kepe V; Berk M; Li J; Ko HK; Li Z; Petro M; DiFilippo FP; Lee Z; Sharifi N
J Biol Chem; 2018 Nov; 293(46):17829-17837. PubMed ID: 30262668
[TBL] [Abstract][Full Text] [Related]
20. Role of the UGT2B17 deletion in exemestane pharmacogenetics.
Luo S; Chen G; Truica C; Baird CC; Leitzel K; Lazarus P
Pharmacogenomics J; 2018 Apr; 18(2):295-300. PubMed ID: 28534527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
